Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
OncoSwab logo — Simplifying lung cancer detection.

OncoSwab

Simplifying lung cancer detection.

Founded 2023 7 employees Seed Biotechnology, Health Care

General Information

Company Name OncoSwab
Founded Year 2023
Employees 7
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, B2C, B2B2C
Revenue Model Service Fee, Usage Based, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with OncoSwab. To contact OncoSwab, visit oncoswab.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OncoSwab compare?

A PDF of OncoSwab and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OncoSwab soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OncoSwab

OncoSwab, founded in 2023, is a biotechnology startup dedicated to revolutionizing lung cancer detection. With the slogan, "Simplifying lung cancer detection," OncoSwab addresses a critical healthcare gap—75% of lung cancer cases are currently detected too late. Their innovative approach aims to provide a non-invasive, user-friendly testing method to catch the disease earlier.

The company is conducting proof-of-concept trials in collaboration with leading hospitals and lung cancer experts in the US and Europe, showcasing solid potential to impact global health positively. Backed by the Health Wildcatters Accelerator and the Swiss Government's DayOne Tech, OncoSwab received a Seed Round investment on 11 September 2023, further supported by several pre-seed investors.

With offices strategically located in San Francisco, California and Corroux, Switzerland, OncoSwab is well-positioned in the Biotechnology and Health Care industries, aiming to save lives through accessible early cancer detection solutions.

Business keywords: lung cancer detection, early detection, non-invasive testing, medical diagnostics, oncology, point-of-care testing, high-risk screening, proof-of-concept trials, startup accelerator support, medical research collaboration, medical device development

Services & Products

Nasal swab sampling for lung cancer research
Extraction and analysis of airway-derived genetic material
Research Use Only platform for biomarker studies

Target Customers

Cancer researchers Clinical study teams Biomarker discovery specialists Oncology research institutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 1
Health Wildcatters
Health Wildcatters
11 Sep 2023

OncoSwab Alternatives & Competitors

View All Alternatives
OncoSwab vs
VisionGate, Inc.
VisionGate, Inc. United States

Leading the Battle Against Lung Cancer through our Early Detection Technology

Venture round
24 employees
Biotechnology, Health Care
OncoSwab vs
Nucleix Ltd.
Nucleix Ltd. Israel

Developing cancer diagnostic panels based on epigenetic bio markers

72 employees
Biotechnology, Health Care
OncoSwab vs
Vigilant Biosciences, Inc.
Vigilant Biosciences, Inc. United States

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the ea...

Venture round
21 employees
Biotechnology, Health Care
View all alternatives

FAQ About OncoSwab

Simplifying lung cancer detection.
OncoSwab was founded in 2023.
OncoSwab operates in Biotechnology and Health Care. Its work centres on lung cancer detection, early detection, non-invasive testing and medical diagnostics. Its customers include Cancer researchers, Clinical study teams and Biomarker discovery specialists.
OncoSwab has a B2B, B2C and B2B2C business model. Its revenue comes from Service Fee, Usage Based and Data Monetization.
OncoSwab has approximately 7 employees.
OncoSwab has completed 1 funding round. The latest funding stage is Seed.
OncoSwab offers: Nasal swab sampling for lung cancer research, Extraction and analysis of airway-derived genetic material, Research Use Only platform for biomarker studies.
Top alternatives and competitors to OncoSwab include VisionGate, Inc., Nucleix Ltd., Vigilant Biosciences, Inc., Rarecells , Beacon Biomedical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OncoSwab and VisionGate, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OncoSwab, https://bouncewatch.com/company/oncoswab, updated 17 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout